CAR-T cells are revolutionizing the treatment of cancer and other diseases. A latest iteration in development involves fusion with an antigen-based CAR enhancer to provide low-affinity IL-2 signaling that might limit adverse effects.Yuzhe Shi...
FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma Article Open access 25 August 2024 c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation Article 19 June 2023 A multi-kinase ...
BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to mitigate these limitations. Methods We constructed...
B. IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol. 167, 6869–6876 (2001). Article CAS PubMed Google Scholar Rathmell, J. C., Elstrom, R. L., Cinalli, R. M. & Thompson, C. B. Activated Akt promotes increased resting T cell size, CD28-...
(s) role in normal plasma cells and MM development, evaluated as well as the potential side effects of its targeting by different CAR-T cells generations. In conclusion, BCMA can be regarded as an ideal molecule to be targeted in immunotherapeutic methods, regarding lower potential systemic and...
Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation or loss. Dual antigen targeting could potentially prevent this, but the clinical safety...
However, research progress on the use of CAR-T for ovarian cancer is yet to make a breakthrough; conversely, the neurotoxicity and systemic side effects of CAR-T cells have been reported in multiple instances [9, 10]. Based on preclinical evidence, CAR-T cells need to exhibit moderate ...
This is not the case in AML where the surface proteome of leukemic cells bears a high degree of similarity to that of normal hematopoietic stem/progenitor cells (HSPCs).13 Thus, while CD19 and BCMA stand out as clinically validated CAR targets in FDA-approved CAR T cell products, optimal ...
LAG-3 is mainly expressed on activated T and B cells, NK cells, and dendritic cells (DCs) under physiological conditions, and it can negatively regulate T cell function [24]. Interestingly, LAG-3 was also found to be expressed on a proportion of malignant B cells from patients with diffuse...
(41%) were triple- and penta-refractory, respectively. Forty-three of 70 patients received prior BCMA CAR T cells, 18 received prior BCMA BsAb, and 5 received both. The ORR was 65.7%, while the ORR in patients receiving prior BCMA BsAb was lower than that in patients receiving prior ...